Airway mucus is a multilayered substance consisting of visoelastic protein gel, a liquid layer, and a thin layer of surfactant.
Mucus is a gel primarily made of mucin polymers cross-linked by disulfide bonds, along with other components like DNA and actin in purulent secretions.
Mucolytics break these structures:
Mucus is cleared from the airway, primarily by the action of mucociliary clearance and interaction with airflow-cough.
In acute respiratory failure, airway irritation from relatively dry inhaled gases, infection, and inflammation can lead to mucus, hypersecretion, and sedation and neuromuscular impairment can contribute to impaired cough.
Mucolytics are mucoactive agents that alter the physical or chemical properties of airway secretions to reduce viscosity and improve clearance by cough and mucociliary transport.
Mucolytics are medications that thin (reduce the viscosity of) mucus in the airways, making it easier to cough up and clear from the lungs.
They are used adjunctively—not as replacements for other therapies—in muco-obstructive lung diseases including COPD/chronic bronchitis, cystic fibrosis (CF), and bronchiectasis.
Mucoactive therapies include those designed to increase clearance through rehydration of the mucus layer and increase cough, and those alter viscoelastic properties of secreted mucus.
Mucoactive agents also include expectorants (increase secretion volume/hydration), mucokinetics (improve mucus transport), and mucoregulators (modulate mucus production).
The evidence of benefit of mucolytics is questionable.
Mucolytics are not entirely benign with direct pharmacologic side effects of bronchoconstriction and gastrointestinal adverse events, and some nebulizer therapy must be administered by a respiratory therapist, frequently use requires installation and removal of an in-line filter, which can lead the loss of positive end expiratory pressure, decruitment and hypoxemia.
Classic thiol-based mucolytics (N-acetylcysteine, erdosteine, mecysteine): Contain free sulfhydryl groups that cleave the disulfide bonds linking mucin polymers, depolymerizing the mucin network.
Classic mucolytics are thiol-based—Break disulfide bonds in mucin polymers via thiol-disulfide interchange, reducing viscosity.
They also have antioxidant, anti-inflammatory, and antibacterial properties and can replenish intracellular glutathione.
Carbocysteine: A thiol derivative better described as a mucoregulator—it lacks a free SH group and instead normalizes mucus by restoring fucose/sialic acid content in mucins and increasing airway chloride transport, improving hydration.
Ambroxol and bromhexine (mucokinetics/surfactant stimulators): Stimulate surfactant secretion and reduce sputum adhesiveness, enhancing ciliary clearance.
Peptide/enzymatic mucolytic — dornase alfa (recombinant human DNase): Peptide mucolytics — Hydrolyze extracellular DNA and/or F-actin polymers that make pus thick and sticky, especially useful in cystic fibrosis. The main example is dornase alfa.
Enzymatically degrades extracellular DNA (and F-actin copolymers) derived from neutrophils in purulent CF mucus.
Hydrators/expectorants (hypertonic saline, mannitol, guaifenesin): Increase airway surface liquid to aid detachment; guaifenesin is generally ineffective, whereas hypertonic saline and dry-powder mannitol can help in CF and non-CF bronchiectasis.
Efficacy by disease
COPD / chronic bronchitis: Oral mucolytics can modestly reduce exacerbations and improve health status; benefit is most established for higher-dose agents.
Guidance conflicts exist among respiratory experts about mucolytics and their benefits.
Cystic fibrosis: Dornase alfa is a cornerstone therapy, improving lung function and reducing exacerbations; it is FDA-approved to improve pulmonary function and reduce risk of respiratory infections requiring parenteral antibiotics in patients with FVC ≥40% predicted, alongside standard therapies.
Evidence for oral/nebulized thiol derivatives in CF is less clear.
Bronchiectasis (non-CF): Dornase alfa is contraindicated—a trial showed worsened lung function and exacerbation rates—and it is reported to increase mortality when used outside CF.
Hyperosmolar agents are the better-supported option.
Children with chronic suppurative lung disease: Evidence is scarce despite extrapolation from adult data.
In a trial of carbocisteine or hypertonic saline in mechanically, ventilated patients in acute respiratory failure with difficult to clear secretions there was no reduction in the duration of mechanical ventilation with either type therapy and potential signal for harm was noted: upper gastrointestinal bleeding occurred with carbocisteine and bronchoconstriction was more common among patients with hypertonic saline (Connolly B).
Hydration/expectorant effects in CF Guaifenesin (e.g., Mucinex) is often marketed as an expectorant rather than a true mucolytic; evidence for its effectiveness in many conditions is limited.
Primarily chronic lung diseases involving thick mucus (muco-obstructive diseases):
Chronic obstructive pulmonary disease (COPD), especially chronic bronchitis and emphysema
Cystic fibrosis (CF) Bronchiectasis Sometimes pneumonia, acute exacerbations, or preparation for procedures like bronchoscopy
Tracheostomy care They help reduce mucus plugging, improve clearance, and may lower infection risk or exacerbation rates in some cases (evidence is stronger for certain agents like NAC or erdosteine in COPD, and dornase alfa in CF).
Administration
Often inhaled via nebulizer (especially NAC and dornase alfa) for direct airway effect.
Oral forms (capsules, tablets, syrups) for others like carbocysteine or erdosteine.
NAC can also be given IV or orally for acetaminophen overdose.
Common side effects include nausea, vomiting, diarrhea, rash, sore throat, voice changes/hoarseness, and rarely shortness of breath.
NAC by inhalation can cause bronchospasm. Avoid combining with cough suppressants, as this can lead to mucus accumulation. Contraindications typically include hypersensitivity; some caution in peptic ulcer disease or certain other conditions.